Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes

被引:4
|
作者
Tan, Jinlin [1 ]
Wu, Zhilong [2 ]
Hu, Peipei [3 ]
Gan, Lin [4 ]
Wang, Ying [1 ]
Zhang, Dingmei [1 ,5 ]
机构
[1] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510080, Peoples R China
[2] Fourth Peoples Hosp Foshan City, Foshan 528000, Peoples R China
[3] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China
[4] Huangpu Dist Ctr Dis Control & Prevent, Guangzhou 510700, Peoples R China
[5] NMPA Key Lab Qual Monitoring & Evaluat Vaccines &, Guangzhou 510080, Peoples R China
来源
PATHOGENS | 2022年 / 11卷 / 09期
关键词
SARS-CoV-2; PLpro; COVID-19; mutation; outcome; INSIGHTS;
D O I
10.3390/pathogens11091008
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Papain-like protease (PLpro) is important for the replication and transcription of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to reveal the PLpro mutations associated with the clinical outcomes of patients. Due to the importance of the S protein in the pathogenicity of SARS-CoV-2, the mutation of the S protein was also analyzed in this study. After downloading the data from the Global Initiative on Sharing Avian Influenza Data (GISAID) database, samples were divided into two groups on the basis of patient status, namely, recovered and dead groups. This study performed a univariate analysis and further explored the association of mutations with patient outcomes through multivariate logistic regression analysis. A total of 138,492 samples were used for analysis. The patients had a mean age of 43.66 +/- 21.56 years, and 51.3% of them were female. Multivariate logistic regression results showed that, compared with men, women had a lower risk of dying from coronavirus disease 2019 (COVID-19) (OR = 0.687, 95%CI: 0.638-0.740). Compared with patients aged 17 years and younger, patients aged 18-64 years (OR = 2.864, 95%CI: 1.982-4.139) and patients over 65 years old (OR = 19.135, 95%CI: 13.280-27.572) had a higher risk of death after infection. Compared with the wild type, P78L (OR = 5.185, 95%CI: 2.763-9.730) and K233Q (OR = 5.154, 95%CI: 1.442-18.416) in PLpro were associated with an increased risk of death. A synergistic interaction existed between age and mutations A146D and P78L. The results of the multivariate logistic regression analysis of the data on vaccinated patients demonstrated that, compared with the wild type, the P78L (OR = 3.376, 95%CI: 2.040-5.585) mutation was associated with an increased risk of death. In conclusion, compared with the wild-type PLpro protein, the P78L and K233Q mutations may increase the risk of death in infected individuals. In addition, a synergistic effect existed between age and P78L and K233Q that increased the risk of death in older patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
    Klemm, Theresa
    Ebert, Gregor
    Calleja, Dale J.
    Allison, Cody C.
    Richardson, Lachlan W.
    Bernardini, Jonathan P.
    Lu, Bernadine G. C.
    Kuchel, Nathan W.
    Grohmann, Christoph
    Shibata, Yuri
    Gan, Zhong Yan
    Cooney, James P.
    Doerflinger, Marcel
    Au, Amanda E.
    Blackmore, Timothy R.
    van der Heden van Noort, Gerbrand J.
    Geurink, Paul P.
    Ovaa, Huib
    Newman, Janet
    Riboldi-Tunnicliffe, Alan
    Czabotar, Peter E.
    Mitchell, Jeffrey P.
    Feltham, Rebecca
    Lechtenberg, Bernhard C.
    Lowes, Kym N.
    Dewson, Grant
    Pellegrini, Marc
    Lessene, Guillaume
    Komander, David
    EMBO JOURNAL, 2020, 39 (18):
  • [2] Identification of novel allosteric sites of SARS-CoV-2 papain-like protease (PLpro) for the development of COVID-19 antivirals
    Ferreira, Juliana C.
    Villanueva, Adrian J.
    Al Adem, Kenana
    Fadl, Samar
    Alzyoud, Lara
    Ghattas, Mohammad A.
    Rabeh, Wael M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (11)
  • [3] Understanding the active site of the SARS-CoV-2 papain-like protease (PLPro)
    Balogun, MaryAgnes
    Wu, Amy Wu
    Bacorn, Mickayla
    Olivas, Cassandra
    Zardecki, Christine
    Lubin, Joseph
    Khare, Sagar
    Burley, Stephen
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2021, 77 : A311 - A311
  • [4] Identification of Triazolopyrimidinyl Scaffold SARS-CoV-2 Papain-Like Protease (PLpro) Inhibitor
    Kralj, Sebastjan
    Jukic, Marko
    Bahun, Miha
    Kranjc, Luka
    Kolaric, Anja
    Hodoscek, Milan
    Ulrih, Natasa Poklar
    Bren, Urban
    PHARMACEUTICS, 2024, 16 (02)
  • [5] Genetically Encoded Fluorescent Sensors for SARS-CoV-2 Papain-like Protease PLpro
    Sokolinskaya, Elena L.
    Putlyaeva, Lidia, V
    Polinovskaya, Vasilisa S.
    Lukyanov, Konstantin A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [6] Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PLpro)
    Taylor, Ashley J.
    Amporndanai, Kangsa
    Rietz, Tyson A.
    Zhao, Bin
    Thiruvaipati, Anusha
    Wei, Qiangqiang
    South, Taylor M.
    Crow, Mackenzie M.
    Apakama, Chideraa
    Sensintaffar, John L.
    Phan, Jason
    Lee, Taekyu
    Fesik, Stephen W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (08): : 1351 - 1357
  • [7] Structure of SARS-CoV-2 papain-like protease PLpro reveals a framework for antiviral inhibitor design
    Srinivasan, Vasundara
    Werner, Nadine
    Falke, Sven
    Brognaro, Hevila
    Guenther, Sebastian
    Reinke, Patrick Y. A.
    Atia-tul-Wahab
    Choudhary, Iqbal
    Meents, Alke
    Betzel, Christian
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2021, 77 : C198 - C198
  • [8] Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach
    Sencanski, Milan
    Perovic, Vladimir
    Milicevic, Jelena
    Todorovic, Tamara
    Prodanovic, Radivoje
    Veljkovic, Veljko
    Paessler, Slobodan
    Glisic, Sanja
    CHEMISTRYOPEN, 2022, 11 (02):
  • [9] Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
    Garnsey, Michelle R.
    Robinson, Matthew C.
    Nguyen, Luong T.
    Cardin, Rhonda
    Tillotson, Joseph
    Mashalidis, Ellene
    Yu, Aijia
    Aschenbrenner, Lisa
    Balesano, Amanda
    Behzadi, Amin
    Boras, Britton
    Chang, Jeanne S.
    Eng, Heather
    Ephron, Andrew
    Foley, Tim
    Ford, Kristen K.
    Frick, James M.
    Gibson, Scott
    Hao, Li
    Hurst, Brett
    Kalgutkar, Amit S.
    Korczynska, Magdalena
    Lengyel-Zhand, Zsofia
    Gao, Liping
    Meredith, Hannah R.
    Patel, Nandini C.
    Polivkova, Jana
    Rai, Devendra
    Rose, Colin R.
    Rothan, Hussin
    Sakata, Sylvie K.
    Vargo, Thomas R.
    Qi, Wenying
    Wu, Huixian
    Liu, Yiping
    Yurgelonis, Irina
    Zhang, Jinzhi
    Zhu, Yuao
    Zhang, Lei
    Lee, Alpha A.
    SCIENCE ADVANCES, 2024, 10 (35):
  • [10] Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
    Lu, Yongzhi
    Yang, Qi
    Ran, Ting
    Zhang, Guihua
    Li, Wenqi
    Zhou, Peiqi
    Tang, Jielin
    Dai, Minxian
    Zhong, Jinpeng
    Chen, Hua
    He, Pan
    Zhou, Anqi
    Xue, Bao
    Chen, Jiayi
    Zhang, Jiyun
    Yang, Sidi
    Wu, Kunzhong
    Wu, Xinyu
    Tang, Miru
    Zhang, Wei K.
    Guo, Deyin
    Chen, Xinwen
    Chen, Hongming
    Shang, Jinsai
    NATURE COMMUNICATIONS, 2024, 15 (01)